Telomerase inhibition, telomere shortening, and decreased cell proliferation by cell permeable 2'-O-methoxyethyl oligonucleotides
- PMID: 12459009
- DOI: 10.1021/jm025563v
Telomerase inhibition, telomere shortening, and decreased cell proliferation by cell permeable 2'-O-methoxyethyl oligonucleotides
Abstract
Telomerase is an attractive target for chemotherapy. Testing this hypothesis will require potent inhibitors with favorable pharmacokinetic properties. We report that 2'-methoxyethyl oligonucleotides complementary to the telomerase RNA component diffuse across cell membranes without the need for cationic carrier lipid, inhibit telomerase, and cause telomeres to shorten. The ability of antitelomerase oligomers to enter cells without the need to add lipid will simplify preclinical studies and may suggest advantages for clinical use.
Similar articles
-
Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death.Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14276-81. doi: 10.1073/pnas.96.25.14276. Proc Natl Acad Sci U S A. 1999. PMID: 10588696 Free PMC article.
-
Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.Cancer Res. 2003 Sep 15;63(18):5917-25. Cancer Res. 2003. PMID: 14522918
-
Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors.Oncogene. 2002 Jan 21;21(4):638-42. doi: 10.1038/sj.onc.1205064. Oncogene. 2002. PMID: 11850790
-
Telomerase inhibition, oligonucleotides, and clinical trials.Oncogene. 2002 Jan 21;21(4):631-7. doi: 10.1038/sj.onc.1205063. Oncogene. 2002. PMID: 11850789 Review.
-
Targeting human telomerase in cancer therapy.Curr Med Chem Anticancer Agents. 2002 Sep;2(5):577-87. doi: 10.2174/1568011023353822. Curr Med Chem Anticancer Agents. 2002. PMID: 12678725 Review.
Cited by
-
Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.Nat Rev Cancer. 2022 Sep;22(9):515-532. doi: 10.1038/s41568-022-00490-1. Epub 2022 Jul 5. Nat Rev Cancer. 2022. PMID: 35790854 Review.
-
Mapping targetable sites on human telomerase RNA pseudoknot/template domain using 2'-OMe RNA-interacting polynucleotide (RIPtide) microarrays.J Biol Chem. 2012 May 25;287(22):18843-53. doi: 10.1074/jbc.M111.316596. Epub 2012 Mar 26. J Biol Chem. 2012. PMID: 22451672 Free PMC article.
-
Non-coding RNAs as drug targets.Nat Rev Drug Discov. 2017 Mar;16(3):167-179. doi: 10.1038/nrd.2016.117. Epub 2016 Jul 22. Nat Rev Drug Discov. 2017. PMID: 27444227 Free PMC article. Review.
-
Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer.Prostate. 2010 May 1;70(6):616-29. doi: 10.1002/pros.21096. Prostate. 2010. PMID: 20043297 Free PMC article.
-
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.Nucleic Acids Res. 2018 Feb 28;46(4):1584-1600. doi: 10.1093/nar/gkx1239. Nucleic Acids Res. 2018. PMID: 29240946 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources